Regular ArticlePhase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma
References (19)
- et al.
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish ovarian study group trial (DACOVA)
Gynecol Oncol
(1993) - et al.
Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide
Gynecol Oncol
(1991) - et al.
Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy
Eur J Cancer
(1991) - et al.
A phase I study of a daily x 3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer
Gynecol Oncol
(1998) - et al.
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
Gynecol Oncol
(1999) Ovarian cancer. Part II. Treatment
Curr Probl Cancer
(1992)Future directions in the chemotherapy of ovarian cancer
Semin Oncol
(1997)- et al.
Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy
Ann Oncol
(1993) - et al.
Advanced epithelial ovarian cancer: 1998 consensus statements
Ann Oncol
(1999)
Cited by (50)
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)-KCSG GY10-10
2015, Gynecologic OncologyCitation Excerpt :Vinorelbine is a semisynthetic vinca alkaloid. Its activity as a single agent or in combination with other agents for the treatment of platinum-resistant recurrent ovarian cancer has been demonstrated in several phase II studies (Table 1) [8–13]. Vinorelbine has been shown to exert in vitro synergistic effects in combination with gemcitabine and administration of vinorelbine prior to gemcitabine increases the maximum concentration and total area of under curve of gemcitabine [14].
Cancers Arising in the Ovary
2014, Abeloff's Clinical Oncology: Fifth EditionThe predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
2010, Gynecologic OncologyCitation Excerpt :Primary or secondary platinum resistance signalizes a situation with a dismal prognosis. Several regimens have been investigated, but the results have so far been disappointing with response rates around 20% and little or no convincing effect on survival [1–3]. Most ovarian cancer patients end up being multiresistant to cytostatic therapy and are left with few treatment options.
Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
2009, Seminars in OncologyCitation Excerpt :The decision of whether and when to use oral etoposide is influenced by the degree of gastrointestinal complications caused by the patient's cancer as she must be able to tolerate oral therapy in order to have a chance of benefit from this agent. Vinorelbine,60-62 cyclophosphamide, ifosfamide,63,64 and melphalan65 also have been used to treat recurrent disease, with response rates ranging from 10% to 20%, and these drugs may be considered for those patients who have continued relative sensitivity to chemotherapy and have received the more commonly used agents. Hexamethylmelamine (RR, 10%-17%)66-71 is an oral agent that is approved for the treatment of patients with recurrent ovarian carcinoma, although its use is limited by gastrointestinal toxicity.
- 1
To whom correspondence and reprint requests should be addressed. Fax: +45 65 41 29 57. E-mail: [email protected].